EQUITY RESEARCH - ANALYST MEETING







BANGKOK DUSIT MEDICAL SERVICES

BDMS TB

THAILAND / HEALTH CARE SERVICES



Key takeaways from analyst meeting

TARGET PRICE THB35.00 CLOSE THB29.00 UP/DOWNSIDE +20.7% TP vs CONSENSUS -0.2%

Highlights

- We have a neutral view from the 1Q24 analyst meeting.
- Management maintained its 2024 revenue growth guidance of 10-12% in 2024 (vs our 10% assumption), with an EBITDA margin of 24-25% (vs our 24.7% assumption).
- Revenue growth should experience a slowdown in April due to seasonal effects. On a positive note, Middle East patient revenue jumped 25% y-y in April after Ramadan ended. Note Ramadan was from 10 Mar to 9 Apr in 2024 vs 22 Mar to 21 Apr in 2023.
- Revenue from Kuwaiti patients fell by 40% y-y in 1Q24 following Kuwait's government policy to cut payment guarantees for citizens seeking treatment overseas. BDMS commented that the Kuwait government would finalize Thailand's approved hospital list (possibly 2-3 hospitals) for their citizens to get the guarantee of payment (GOP) for medical treatments by the end of 2Q24, and it is likely to be on the list.
- BDMS has recently raised the overall salary for their staff by 10%.
 Thus, the minimum wage hike would have no impact on BDMS.
- BDMS expects insurance patient revenue contribution to increase from 38% (30% for Thai and 8% for international) in 1Q24 to 50% by the next five years. BDMS recently launched an exclusive insurance package (smaller insured amount compared to the current one) with Allianz Ayudhya to attract more middle-income customers.

Outlook and recommendation

- We expect the y-y revenue growth momentum to continue in 2Q24, driven by strong organic growth.
- We maintain our forecast and our 2024 DCF-TP of THB35.0/shr.
 BDMS is trading at an attractive valuation of 28x 2024E P/E, lower than its five-year average of 31x.

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	102,110	112,311	121,304	131,022
Net profit	14,375	16,413	17,928	19,652
EPS (THB)	0.90	1.03	1.13	1.24
vs Consensus (%)	-	4.5	4.9	4.6
EBITDA	24,740	27,717	30,179	32,859
Recurring net profit	14,375	16,413	17,928	19,652
Core EPS (THB)	0.90	1.03	1.13	1.24
EPS growth (%)	14.0	14.2	9.2	9.6
Core P/E (x)	32.1	28.1	25.7	23.5
Dividend yield (%)	2.2	2.4	2.5	2.7
EV/EBITDA (x)	19.1	17.0	15.5	14.1
Price/book (x)	4.8	4.6	4.3	4.0
Net debt/Equity (%)	8.8	6.2	1.1	(3.9)
ROE (%)	15.5	16.8	17.3	17.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	4.5	4.5	(1.7)
Relative to country (%)	5.9	5.2	9.9
Mkt cap (USD m)			12,755
3m avg. daily turnover (USD m))		31.2
Free float (%)			70
Major shareholder	Prasert Pr	asarttong-O	soth (13%)
12m high/low (THB)		3	0.00/25.00
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFAFundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: BDMS - 1Q24 results summary

	1Q23	2Q23	3Q23	4Q23	1Q24	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	24,313	24,372	26,699	26,726	26,930	1	11	102,110	112,311	10
- Hospital revenue	23,084	23,141	25,473	25,379	25,526	1	11	97,077	106,875	10
- Other revenue	1,229	1,232	1,227	1,346	1,404	4	14	5,034	5,436	8
COGS (incl depreciation)	(15,122)	(15,432)	(16,469)	(16,389)	(16,736)	2	11	(63,412)	(69,333)	9
Gross profit	9,191	8,940	10,230	10,337	10,194	(1)	11	38,698	42,979	11
SG&A	(4,633)	(4,876)	(5,106)	(5,191)	(4,893)	(6)	6	(19,806)	(21,504)	g
Operating profit ¹⁾	4,558	4,064	5,124	5,146	5,301	3	16	18,892	21,475	14
Net other income	12	5	7	19	9	(52)	(25)	43	48	10
Interest income	26	48	48	52	48	(7)	87	173	110	(37)
Interest expense	(164)	(134)	(122)	(126)	(113)	(11)	(31)	(547)	(501)	(8)
Pretax profit	4,432	3,983	5,057	5,091	5,246	3	18	18,563	21,131	14
Income Tax	(880)	(812)	(1,025)	(1,038)	(1,042)	0	18	(3,755)	(4,226)	13
Associates	34	13	21	22	13	(41)	(62)	89	98	10
Minority interest	(116)	(120)	(163)	(123)	(143)	16	23	(522)	(590)	13
Core profit	3,470	3,063	3,890	3,952	4,074	3	17	14,375	16,413	14
Extraordinaries, GW & FX								0	0	
Reported net profit	3,470	3,063	3,890	3,952	4,074	3	17	14,375	16,413	14
Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	C
Core EPS (THB)	0.22	0.19	0.24	0.25	0.26	3	17	0.90	1.03	14
EPS (THB)	0.22	0.19	0.24	0.25	0.26	3	17	0.90	1.03	14
LF3 (IND)	0.22	0.19	0.24	0.23	0.20	3	"	0.50	1.03	14
COGS (excl depreciation)	13,693	13,986	14,999	14,886	15,259	3	11	57,564	63,090	10
Depreciation	1,429	1,446	1,470	1,503	1,477	(2)	3	5,848	6,243	7
EBITDA ²⁾	5,987	5,510	6,594	6,649	6,778	2	13	24,740	27,717	12
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	38	37	38	38.7	37.9	(1)	0	38	38	C
SG&A/Revenue	19	20	19	19	18	(1)	(1)	19	19	(0)
EBITDA margin	24.6	22.6	24.7	24.9	25.2	0	1	24	25	C
Net profit margin	14	13	15	15	15	0	1	14	15	1
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	11	10	14	10	12					
OPD volume growth y-y	(7)	0	0							
OPD revenue per head growth y-y	20	10	14							
IPD revenue growth y-y	(2)	10	9	15	9					
IPD volume growth y-y	33	60	20							
IPD revenue per head growth y-y	(26)	(31)	(9)							
Thai revenue growth y-y	(6)	7	9	10	10					
	\ · /									

Note: 1) Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources: BDMS; FSSIA estimates

Exhibit 2: International patient revenue





Exhibit 3: Thai patient revenue



Source: BDMS Source: BDMS

Financial Statements

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	92,968	102,110	112,311	121,304	131,022
Cost of goods sold	(58,329)	(63,412)	(69,333)	(74,787)	(80,610)
Gross profit	34,638	38,698	42,979	46,518	50,413
Other operating income	-	-	-	-	-
Operating costs	(17,655)	(19,806)	(21,504)	(23,104)	(24,824)
Operating EBITDA	22,933	24,740	27,717	30,179	32,859
Depreciation	(5,950)	(5,848)	(6,243)	(6,766)	(7,271)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	16,984	18,892	21,475	23,413	25,588
Net financing costs	(552)	(373)	(391)	(358)	(288)
Associates	42	89	98	108	119
Recurring non-operating income	50	133	146	161	177
Non-recurring items	0	0	0	0	0
Profit before tax	16,481	18,652	21,230	23,216	25,477
Tax	(3,227)	(3,755)	(4,226)	(4,622)	(5,072)
Profit after tax	13,254	14,897	17,003	18,595	20,406
Minority interests	(648)	(522)	(590)	(667)	(753)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	12,606	14,375	16,413	17,928	19,652
Non-recurring items & goodwill (net) Recurring net profit	0 12,606	0 14,375	0 16,413	0 17,928	0 19,652
	12,000	14,373	10,413	17,920	19,032
Per share (THB)	0.70	0.00	1.02	1 12	1.24
Recurring EPS *	0.79	0.90	1.03	1.13	1.24
Reported EPS	0.79	0.90	1.03	1.13	1.24
DPS Diluted shares (used to calculate per share data)	0.50 15,892	0.65 15,892	0.70 15,892	0.72 15,892	0.79 15,892
Growth	15,692	15,692	15,692	13,692	15,692
Revenue (%)	23.1	9.8	10.0	8.0	8.0
Operating EBITDA (%)	32.2	7.9	12.0	8.9	8.9
Operating EBIT (%)	54.1	11.2	13.7	9.0	9.3
Recurring EPS (%)	63.0	14.0	14.2	9.2	9.6
Reported EPS (%)	58.8	14.0	14.2	9.2	9.6
Operating performance	00.0			J.2	0.0
Gross margin inc. depreciation (%)	37.3	37.9	38.3	38.3	38.5
Gross margin exc. depreciation (%)	43.7	43.6	43.8	43.9	44.0
Operating EBITDA margin (%)	24.7	24.2	24.7	24.9	25.1
Operating EBIT margin (%)	18.3	18.5	19.1	19.3	19.5
Net margin (%)	13.6	14.1	14.6	14.8	15.0
Effective tax rate (%)	19.6	20.2	20.0	20.0	20.0
Dividend payout on recurring profit (%)	63.0	71.9	67.8	64.1	63.9
Interest cover (X)	30.8	51.0	55.3	65.9	89.5
Inventory days	14.7	14.7	14.7	14.8	14.8
Debtor days	38.5	39.4	37.6	34.8	32.2
Creditor days	39.1	41.5	41.8	42.2	42.2
Operating ROIC (%)	15.8	16.1	17.5	18.6	19.9
ROIC (%)	12.7	13.1	14.4	15.3	16.5
ROE (%)	14.5	15.5	16.8	17.3	17.8
ROA (%)	10.1	10.7	11.8	12.2	12.7
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Revenue by Division (THB m) Thai patient revenue	2022 67,286	2023 70,866	2024E 76,733	2025E 82,741	2026E 89,217

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

Bangkok Dusit Medical Services					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Depreciation	5,950	5,848	6,243	6,766	7,271
Associates & minorities	0,000	5,040	0,240	0,700	7,271
Other non-cash items	1,275	1,203	590	667	753
Change in working capital	720	161	1,291	1,142	1,234
Cash flow from operations	20,551	21,588	24,537	26,503	28,910
Capex - maintenance	(14,953)	(11,612)	(11,231)	(9,704)	(10,482)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(386)	(290)	0	0	0
Other investments (net)	•	` -	-	-	-
Cash flow from investing	(15,340)	(11,902)	(11,231)	(9,704)	(10,482)
Dividends paid	(7,943)	(10,343)	(11,124)	(11,489)	(12,550)
Equity finance	0	0	0	0	0
Debt finance	4,764	(5,460)	(500)	(500)	(500)
Other financing cash flows	299	612	0	0	0
Cash flow from financing	(2,880)	(15,190)	(11,624)	(11,989)	(13,050)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	2,330	(5,505)	1,681	4,810	5,379
Free cash flow to firm (FCFF)	5,842.84	10,232.29	13,806.49	17,285.67	18,901.18
Free cash flow to equity (FCFE)	10,273.66	4,838.23	12,805.74	16,298.92	17,928.43
Per share (THB)					
	0.27	0.64	0.87	1.09	1.19
FCFF per share FCFE per share	0.37 0.65	0.64	0.87	1.09	1.19
FCFE per snare Recurring cash flow per share	0.65 1.25	0.30 1.35	0.81 1.46	1.03	1.13 1.74
Tiodanning dadit new per ditare	1120			1.00	
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	155,412	165,315	176,546	186,250	196,732
Less: Accumulated depreciation	(63,503)	(67,642)	(73,884)	(80,650)	(87,921)
Tangible fixed assets (net)	91,909	97,673	102,662	105,600	108,811
Intangible fixed assets (net)	19,160	19,376	19,376	19,376	19,376
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	1,986	2,276	2,276	2,276	2,276
Cash & equivalents	14,972	9,467	11,148	15,958	21,337
A/C receivable	10,484	11,558	11,558	11,558	11,558
Inventories	2,211	2,420	2,652	2,859	3,083
Other current assets	132	101	111	120	130
Current assets	27,799	23,545	25,469	30,495	36,107
Other assets	689	726	726	726	726
Total assets	141,543	143,596	150,508	158,472	167,295
Common equity	89,879	95,242	100,531	106,970	114,072
Minorities etc.	3,834	3,630	4,220	4,887	5,641
Total shareholders' equity	93,713	98,872	104,752	111,857	119,713
Long term debt	23,062	18,134	17,634	17,134	16,634
Other long-term liabilities	10,032	10,973	10,973	10,973	10,973
Long-term liabilities	33,094	29,107	28,607	28,107	27,607
A/C payable	6,176	6,901	7,564	8,155	8,792
Short term debt	532	0	0	0	0
Other current liabilities	8,028	8,715	9,586	10,353	11,183
Current liabilities	14,736	15,616	17,149	18,508	19,975
Total liabilities and shareholders' equity	141,543	143,596	150,508	158,472	167,295
Net working capital	(1,377)	(1,538)	(2,828)	(3,971)	(5,205)
Invested capital	112,367	118,513	122,211	124,006	125,984
* Includes convertibles and preferred stock which is be	eing treated as debt				
Per share (THB)					
Book value per share	5.66	5.99	6.33	6.73	7.18
Tangible book value per share	4.45	4.77	5.11	5.51	5.96
g acci. raido poi citaro		7.11	0.11	0.01	0.00
Financial strength	т.то				
-		9 0	e o	1 1	/2 O/
Net debt/equity (%)	9.2	8.8	6.2	1.1	(3.9)
Net debt/equity (%) Net debt/total assets (%)	9.2 6.1	6.0	4.3	0.7	(2.8)
Financial strength Net debt/equity (%) Net debt/total assets (%) Current ratio (x)	9.2 6.1 1.9	6.0 1.5	4.3 1.5	0.7 1.6	(2.8)
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x)	9.2 6.1 1.9 19.6	6.0 1.5 14.0	4.3 1.5 33.7	0.7 1.6 46.6	(2.8) 1.8 63.3
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x)	9.2 6.1 1.9	6.0 1.5	4.3 1.5	0.7 1.6	(2.8)
Net debt/equity (%) Net debt/total assets (%)	9.2 6.1 1.9 19.6	6.0 1.5 14.0	4.3 1.5 33.7	0.7 1.6 46.6	(2.8) 1.8 63.3
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) *	9.2 6.1 1.9 19.6 2022	6.0 1.5 14.0 2023	4.3 1.5 33.7 2024E	0.7 1.6 46.6 2025E 25.7	(2.8) 1.8 63.3 2026E
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) *	9.2 6.1 1.9 19.6 2022 36.6	6.0 1.5 14.0 2023 32.1	4.3 1.5 33.7 2024E 28.1	0.7 1.6 46.6 2025E	(2.8) 1.8 63.3 2026E 23.5
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x)	9.2 6.1 1.9 19.6 2022 36.6 44.1	6.0 1.5 14.0 2023 32.1 38.7	4.3 1.5 33.7 2024E 28.1 33.9	0.7 1.6 46.6 2025E 25.7 31.0	(2.8) 1.8 63.3 2026E 23.5 28.3
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	9.2 6.1 1.9 19.6 2022 36.6 44.1 36.6	6.0 1.5 14.0 2023 32.1 38.7 32.1	4.3 1.5 33.7 2024E 28.1 33.9 28.1	0.7 1.6 46.6 2025E 25.7 31.0 25.7	(2.8) 1.8 63.3 2026E 23.5 28.3 23.5
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	9.2 6.1 1.9 19.6 2022 36.6 44.1 36.6 1.7	6.0 1.5 14.0 2023 32.1 38.7 32.1 2.2	4.3 1.5 33.7 2024E 28.1 33.9 28.1 2.4	0.7 1.6 46.6 2025E 25.7 31.0 25.7 2.5	(2.8) 1.8 63.3 2026E 23.5 28.3 23.5 2.7
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation	9.2 6.1 1.9 19.6 2022 36.6 44.1 36.6 1.7 5.1	6.0 1.5 14.0 2023 32.1 38.7 32.1 2.2 4.8	4.3 1.5 33.7 2024E 28.1 33.9 28.1 2.4 4.6	0.7 1.6 46.6 2025E 25.7 31.0 25.7 2.5 4.3	(2.8) 1.8 63.3 2026E 23.5 28.3 23.5 2.7 4.0
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	9.2 6.1 1.9 19.6 2022 36.6 44.1 36.6 1.7 5.1 6.5	6.0 1.5 14.0 2023 32.1 38.7 32.1 2.2 4.8 6.1	4.3 1.5 33.7 2024E 28.1 33.9 28.1 2.4 4.6 5.7	0.7 1.6 46.6 2025E 25.7 31.0 25.7 2.5 4.3 5.3	(2.8) 1.8 63.3 2026E 23.5 28.3 23.5 2.7 4.0 4.9
Net debt/equity (%) Net debt/total assets (%) Current ratio (x) CF interest cover (x) Valuation Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	9.2 6.1 1.9 19.6 2022 36.6 44.1 36.6 1.7 5.1 6.5 20.6	6.0 1.5 14.0 2023 32.1 38.7 32.1 2.2 4.8 6.1 19.1	4.3 1.5 33.7 2024E 28.1 33.9 28.1 2.4 4.6 5.7 17.0	0.7 1.6 46.6 2025E 25.7 31.0 25.7 2.5 4.3 5.3 15.5	(2.8) 1.8 63.3 2026E 23.5 28.3 23.5 2.7 4.0 4.9 14.1

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Bangkok Dusit Medical Serv (BDMS TB)

FSSIA ESG rating

★ ★ ★

Exhibit 4: FSSIA ESG score implication

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA			Domes	stic ratings	;		Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Υ	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High						-	
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based	_	_	91	92	98	94	96	209
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	_	_	1	2	2	2	3	5
Total waste	_	_	6	7	7	5	9	13
Waste recycled	_	_	0	1	1	0	1	2
Waste sent to landfills	_	_	_	_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	_	_	82	82	82	82	83	83
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	_	_	0	0	0	0	0	1
Total recordable incident rate - employees	_	_	2	2	2	1	1	1
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct	-	_	18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance	110	110	110	110	100	100	100	100
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	13	13	14	12	13	12	12	12
Board meeting attendance pct	95	94	98	97	98	98	97	100
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No	No	No	No
, ,		42	43	44		46	47	48
Age of the eldest director	45 83	84	43 85	86	45 87	88	47 89	90
Age of the oldest director			5 5					
No. of executives / company managers	4	5	1	5 2	6	7 2	5 2	5
No. of female executives	1	1 No.			1 No.			2
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating				
The Dow Jones Sustainability ndices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the comp ual S&P Globa ranked compa	ransparent, rules-based panies' Total Sustainabil Il Corporate Sustainabili nies within each industr	lity Scores resulting ty Assessment (CSA). y are selected for	Sustainability A ESG Score of I scoring compa selected from t	ssessment (C ess than 45% ny are disqual he Eligible Un		impanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are
Sustainability nvestment ist (THSI) ist (THSI) ist (Sustainable ist (Sustainability ist (Sust	managing bu Candidates r 1) no irregula float of >150 up capital. So 70%; 2) inde wrongdoing i	usiness with tra must pass the p ar trading of the shareholders, ome key disqua pendent directorelated to CG, s	ty in Environmental and nsparency in Governan- oreemptive criteria, with e board members and e. and combined holding rallifying criteria include: ors and free float violatic social & environmental is urnings in red for > 3 year	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	minimum of 50 during the assenature of the research serious serious capitalization > 0.5% of paid-Index is a mark	% for each indessment year. elevant industr is extended THB5b (~US) up capital for a et capitalisati	sion, verified data dicator, unless the The scoring will I y and materiality. from the THSI oc D150b); 2) free flat least 9 out of 1 on-weighted inde mber of stocks.	e company is a be fairly weigh empanies who oat >20%; and 2 months. The	a part of DJSI ted against the se 1) market d 3) liquidity e SETTHSI
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by t Thailand (SE	he Thai IOD, w	in sustainable developr vith support from the Sto are from the perspective.	ock Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores belo nent of sharel 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) an); 3) the role of
AGM level By Thai nvestors Association TIA) with support from he SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of si exercised. The and verifiability	e incorporated and sufficiently e CG compone AGM procedu and after the m ufficient informatic second assesser; and 3) opennes	nich shareholders' rights into business operations disclosed. All form impounts to be evaluated ann tres before the meeting eeting (10%). (The first a on for voting; and 2) facilitats s 1) the ease of attending m is for Q&A. The third involves, resolutions and voting res	s and information is ortant elements of two roully. The assessment (45%), at the meeting ssesses 1) advance ring how voting rights can be neetings; 2) transparency as the meeting minutes that	ent g n be y				
Private Sector Collective Action Against Corruption CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contro Certification is eciding to become Intent to kick off a soluding risk assess	hecklist include corrupti- ils, and the monitoring a good for three years. e a CAC certified member st an 18-month deadline to sub- ssment, in place of policy are blishment of whistleblowing stakeholders.)	and developing of tart by submitting a pmit the CAC Checklist for nd control, training of	passed Checkl	ist will move fo se members a	ed by a committe or granting certific re twelve highly r achievements.	cation by the 0	CAC Council
Morningstar Sustainalytics	based on an risk is unmar regulatory filing	assessment of naged. Sources gs, news and other	k rating provides an ove f how much of a compar to be reviewed include corp er media, NGO reports/webs. ESG controversies, issuer	ny's exposure to ESG orate publications and sites, multi-sector			score is the sum higher ESG risk Medium		ed risk. The
		iality & peer revie		7000000N 0// G/G/N 200	0-10	10-20	20-30	30-40	40+
ESG Book	positioned to the principle helps explair over-weightin	outperform ov of financial ma n future risk-adj	ustainable companies the rethe long term. The meteriality including informusted performance. Main higher materiality and ly basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s ndicating better p	core is scaled	
<u>MSCI</u>				anagement of financially their exposure to ESG ris					nethodology to
	AAA	8.571-10.000		•		, ,		·	
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most s	gnificant ESG ri	sks and opportunitie	es .	
	A	5.714-7.142							
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to
	ВВ	2.857-4.285							
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manade significan	t ESG risks	
	CCC	0.000-1.428	23		<u>.</u> g.,poc		g_ 0.g0di		
Moody's ESG olutions	believes that	a company int		take into account ESG ol to its business model and medium to long term.					
Refinitiv ESG ating	based on pul	blicly available	and auditable data. The	a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	nce and insufficie	nt degree of ti	
S&P Global				asuring a company's perfossification. The score ran			of ESG risks, op	portunities, an	d impacts
Bloomberg	ESG Score		score is based on Bloor	ating the company's aggr	ncial materiality.	The score is	a weighted gener	alized mean (power mean)
			of Pillar Scores, where	the weights are determin	ed by the pillar p	nonty ranking	. values rarige in	טוווט נט זט; זנ	is the best.

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
24-Jun-2021 19-Apr-2022	BUY BUY	29.00 31.00	06-Oct-2022 08-Jan-2023	BUY BUY	33.00 34.50	18-Jan-2024	BUY	35.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 29.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 16-May-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.